Early-stage biopharma company Uvax Bio chooses Delaware for $8M investment in next level of growth
American Entrepreneurship
MAY 31, 2023
October 24, 2022 ) – Uvax Bio LLC , an early-stage biopharmaceutical company with cutting-edge vaccine platform technology that has produced both COVID-19 and HIV-1 vaccine candidates, has chosen to grow in Newark, Delaware, where it has been headquartered since forming in 2018.
Let's personalize your content